AstraZeneca, Sputnik Light vaccine cocktail elicits high immunogenicity
The combination of the AstraZeneca vaccine (Covishield in India) and the first component of the Sputnik V vaccine (Sputnik Light) has shown a high immunogenicity profile in a clinical trial.
By Newsmeter Network Published on 20 Aug 2021 12:12 PM GMT
Hyderabad: The combination of the AstraZeneca vaccine (Covishield in India) and the first component of the Sputnik V vaccine (Sputnik Light) has shown a high immunogenicity profile in a clinical trial.
The Russian Direct Investment Fund (RDIF), which is Russia's sovereign wealth fund, AstraZeneca, and R-Pharm announced the preliminary results on the immunogenicity of the combined use of AstraZeneca vaccine (developed jointly with the University of Oxford) and Sputnik Light vaccine (based on human Adenovirus serotype 26) from the clinical trial of vaccines in the Republic of Azerbaijan.
The clinical trials in Azerbaijan began in February 2021. To date, 64 volunteers have been vaccinated and the enrolment of volunteers is ongoing. Preliminary data from the first 20 participants showed that antibodies to the SARS-CoV-2 virus spike protein (S-protein) were elicited in 100 percent of cases. The interim analysis of data has previously demonstrated a high safety profile for the combined use of the vaccines with no serious adverse events or cases of Coronavirus infection after vaccination.
The clinical trials of a combination of vaccines are being carried out in several countries as part of a global program. Volunteers are being vaccinated in UAE and Argentina while regulatory approval to conduct trials is granted in Russia and Belarus.
The heterogeneous boosting approach or vaccine cocktail, using the human Adenovirus serotype 26 as the first component and human Adenovirus serotype 5 as the second, was at the core of Sputnik V, the world's first registered vaccine against Coronavirus. With this approach proving successful in creating a longer and more durable immunity against the Coronavirus, the RDIF took the lead in initiating partnerships with other vaccine producers to conduct joint studies of a combination of the first component of Sputnik V with foreign vaccines.
The first partnership of this kind was concluded in December 2020 under President of Russia Vladimir Putin. RDIF, the Gamaleya Center, AstraZeneca and R-Pharm signed a Memorandum of Intent aimed at cooperation in conducting joint clinical trials of safety and immunogenicity of a combination of AstraZeneca vaccine and the first component of Sputnik V.
